Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Clin Infect Dis. 2015 Mar 1;60(5):787-96.
Corey GR1, Rubinstein E2, Stryjewski ME3, Bassetti M4, Barriere SL5.
1Department of Medicine, Duke Clinical Research Institute, Durham, North Carolina.
2Section of Infectious Diseases, Department of Internal Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Canada.
3Department of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas ‘Norberto Quirno’ (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina.
4Infectious Diseases Division, Santa Maria Misericordia University Hospital, Piazzale Santa Maria della Misericordia, Udine, Italy.
5Theravance Biopharma US, Inc., South San Francisco, California.
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and the most frequent invasive infection due to methicillin-resistant S. aureus (MRSA). Treatment is challenging, particularly for MRSA, because of limited treatment options. Telavancin is a bactericidal lipoglycopeptide antibiotic that is active against a range of clinically relevant gram-positive pathogens including MRSA. In experimental animal models of sepsis telavancin was shown to be more effective than vancomycin. In clinically evaluable patients enrolled in a pilot study of uncomplicated SAB, cure rates were 88% for telavancin and 89% for standard therapy. Among patients with infection due to only gram-positive pathogens enrolled in the 2 phase 3 studies of telavancin for treatment of hospital-acquired pneumonia, cure rates for those with bacteremic S. aureus pneumonia were 41% (9/22, telavancin) and 40% (10/25, vancomycin) with identical mortality rates. These data support further evaluation of telavancin in larger, prospective studies of SAB